US stock · Healthcare sector · Medical Devices
Company Logo

Boston Scientific Corporation

BSXNYSE

48.22

USD
+0.28
(+0.58%)
Market Closed
105.78P/E
22Forward P/E
5.01P/E to S&P500
69.308BMarket CAP
- -Div Yield

Boston Scientific Corporation

NYSE:BSX

RECENT
PRICE

48.22

P/E
RATIO

105.78

(PEG:-3.22)

P/E RATIO
RELATIVE
TO S&P

5.01

DIV
YLD

0.09%

High:
Low:

0
0

0
0

0
0

0
0

0
0

0
0

0
0

0
0

0
0

0
0

0
0

0
0

0
0

0
0

0
0

0
0

Legends

Stock price

0.79 Beta (1.0 Market)

0

0

0

0

0

0

0

0

0

-

% total return 03/23:

Stock

S&P

1y.

0

0

3y.

0

0

5y.

0

0

0

Percent shares traded:

0

0

0

2006

2007

2008

2009

2010

2011

2012

2013

2014

2015

2016

2017

2018

2019

2020

2021

2022

Fiscal year

6.14

(2.81)

1.18

- -

5.62

(0.33)

0.38

- -

5.37

(1.36)

0.57

- -

5.43

(0.68)

0.31

- -

5.14

(0.70)

0.03

- -

5.05

0.29

0.47

- -

5.15

(2.89)

0.74

- -

5.33

(0.09)

0.62

- -

5.57

(0.09)

0.76

- -

5.57

(0.18)

0.26

- -

6.18

0.26

0.44

- -

6.60

0.08

0.81

- -

7.11

1.21

(0.00)

- -

7.71

3.38

0.99

- -

7.00

(0.06)

0.80

0.02

8.39

0.73

0.93

0.04

8.87

0.49

0.66

0.04

Revenue per share

Earnings per share

Free Cash Flow per sh

Dividends per share

0.27

12.02

0.24

10.15

0.24

8.79

0.24

8.16

0.18

7.44

0.20

7.52

0.16

4.88

0.18

4.88

0.20

4.88

0.18

4.71

0.28

4.96

0.23

5.12

0.23

6.32

0.33

9.97

0.27

10.82

0.39

11.73

0.41

12.28

CAPEX per share

Book Value per share

1,273

1,487

1,499

1,508

1,518

1,509

1,407

1,341

1,324

1,341

1,358

1,370

1,381

1,392

1,417

1,417

1,431

Comm.Shares outs.(m)

- -

- -

- -

(44.5)

(2.57)

- -

(8.5)

(0.40)

- -

(13.5)

(0.19)

- -

(9.6)

(0.47)

- -

22.8

1.40

- -

(2.0)

(0.13)

- -

(106.1)

(6.23)

- -

(142.8)

(7.87)

- -

(95.8)

(4.78)

- -

82.9

3.74

- -

346.9

14.70

- -

26.5

1.06

- -

11.9

0.49

- -

(642.7)

(16.98)

0.05%

56.3

1.88

0.09%

86.1

4.06

0.09%

Avg. annual P/E ratio

P/E relative to S&P500

Avg. annual div. yield

Capital Structure (31/12/22 | Q4)

Total liabilities
$14,896 m.

Total assets
$32,469 m.

Long-term debt
$8,915 m.

Cash and equiv.
$928 m.

Goodwill $12,920 m.

Retained earnings $(750) m.

Common stock 1,433 m. shares

Market Capitalisation
$68,296 m. (as of 25/3/23)

7,622

11.9%

7,249

(53.4)%

7,143

1.7%

7,380

(4.1)%

7,477

(4.4)%

8,386

5.3%

9,048

14.2%

9,823

15.3%

10,735

14.1%

9,913

(0.8)%

11,888

10.1%

12,682

16.0%

Revenue (m)

Operating margin

717

441

683

(4,068)

689

(121)

725

(119)

769

(239)

815

347

844

104

894

1,671

1,011

4,700

1,123

(82)

1,093

1,041

803

698

Depreciation (m)

Net profit (m)

31.3%

5.8%

0.9%

(56.1)%

45.7%

(1.7)%

76.6%

(1.6)%

63.2%

(3.2)%

(96.0)%

4.1%

88.7%

1.1%

(17.5)%

17.0%

(584.1)%

43.8%

(2.5)%

(0.8)%

3.3%

8.8%

38.8%

5.5%

Income tax rate

Net profit margin

1,298

4,257

11,353

1,250

4,252

6,870

1,187

4,237

6,539

760

3,859

6,457

1,041

5,674

6,320

(348)

5,420

6,733

(1,832)

3,776

7,011

(1,257)

4,771

8,725

(167)

8,579

13,877

3,013

9,118

15,327

2,043

9,190

16,623

1,957

8,915

17,573

Working capital (m)

Long-term debt (m)

Equity (m)

3.3%

4.3%

3.9%

(24.8)%

(22.4)%

(59.2)%

0.4%

0.6%

(1.9)%

(0.5)%

(1.7)%

(1.8)%

(0.9)%

(2.0)%

(3.8)%

5.5%

2.3%

5.2%

1.0%

6.1%

1.5%

12.4%

7.9%

19.2%

30.9%

3.8%

33.9%

1.1%

0.9%

(0.5)%

4.9%

4.4%

6.3%

3.4%

5.0%

4.0%

ROIC

Return on capital

Return on equity

Working Capital

2020

2021

2022

Cash assets

1,734

1,925

928

Receivables

1,531

1,778

1,970

Inventory

1,351

1,610

1,867

Other

2,078

1,004

995

Current assets

6,694

6,317

5,760

Acc. Payable

513

794

862

Debt due

13

261

20

Other

3,155

3,219

2,921

Current liab.

3,681

4,274

3,803

100.0%

- -

100.0%

66.9%

100.0%

- -

100.0%

- -

100.0%

- -

100.0%

- -

100.0%

(18.6)%

100.0%

(7.7)%

100.0%

1,683.3%

100.0%

(8.9)%

134.1%

- -

94.7%

4.2%

Plowback ratio

Div.&Repurch. to FCF

Boston Scientific Corporation (US) started trading on May 2, 1992 (cik: 0000885725), operates in the Healthcare sector (Medical Devices industry), has 41,000 full-time employees, and is led by Mr. Michael F. Mahoney. Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, and atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, cryotherapy ablation systems, and micro and drainage catheters to treat cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.

Annual rates

(avg rate of change)

Past
5 y.

Past
10 y.

Revenues

7.06%

6.83%

Cash flow

-5761.70%

-2559.68%

Earnings

-330.73%

-3.58%

Dividends

- -

- -

Book value

20.92%

12.82%

Insider trading

Type

Shares

Date

Brennan Daniel J.

Sale

30,000

03/02/23

Monson Jonathan

Exempt

5,000

03/01/23

Monson Jonathan

Sale

5,000

03/01/23

Monson Jonathan

Exempt

5,000

03/01/23

Brennan Daniel J.

Exempt

13,661

03/01/23

Fiscal Year Ends

Quarterly Revenue (m)

Full fiscal year

I

II

III

IV

2020

2,543

2,003

2,659

2,709

9,914

2021

2,752

3,077

2,932

3,127

11,888

2022

3,026

3,244

3,170

3,242

12,682

Fiscal Year Ends

Earnings per share

Full fiscal year

I

II

III

IV

2020

0.01

(0.10)

(0.11)

0.15

-0.06

2021

0.24

0.13

0.30

0.07

0.73

2022

0.08

0.18

0.12

0.10

0.48

Fiscal Year Ends

Quarterly dividends paid

Full fiscal year

I

II

III

IV

2020

- -

- -

- -

0.01

0.01

2021

0.01

0.01

0.01

0.01

0.04

2022

0.01

0.01

0.01

0.01

0.04

08/08/2022

Boston Scientific Investigates Whistleblower Report in Vietnam

The Wall Street Journal - Read more...